Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience

Lisa Giulino-Roth, Tara O’Donohue, Zhengming Chen, Tanya M. Trippett, Elizabeth Klein, Nancy A. Kernan, Rachel Kobos, Susan E. Prockop, Andromachi Scaradavou, Neerav Shukla, Peter G. Steinherz, Alison J. Moskowitz, Craig Moskowitz, Farid Boulad

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.

Original languageEnglish (US)
Pages (from-to)1861-1870
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number8
DOIs
StatePublished - Aug 3 2018
Externally publishedYes

Keywords

  • Clinical results
  • lymphoma and Hodgkin disease
  • marrow and stem cell transplantation
  • neoplasia
  • prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience'. Together they form a unique fingerprint.

  • Cite this

    Giulino-Roth, L., O’Donohue, T., Chen, Z., Trippett, T. M., Klein, E., Kernan, N. A., Kobos, R., Prockop, S. E., Scaradavou, A., Shukla, N., Steinherz, P. G., Moskowitz, A. J., Moskowitz, C., & Boulad, F. (2018). Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leukemia and Lymphoma, 59(8), 1861-1870. https://doi.org/10.1080/10428194.2017.1403601